GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ATNM
Actinium is a biotech company specializing in radiopharmaceuticals for cancer treatment. Its stock price is a bet on the growth of this promising area. The chart reflects news from clinical trials and partnerships.
Share prices of companies in the market segment - Cancer blood
Actinium Pharmaceuticals develops targeted radiotherapy that delivers alpha-emitting particles directly to cancer cells. We've classified it under "Blood Cancer" because its developments are targeted at this segment. The chart below shows the market's valuation of the nuclear medicine sector in oncology.
Broad Market Index - GURU.Markets
Actinium Pharmaceuticals develops targeted radiotherapy that delivers alpha-emitting particles directly to cancer cells. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ATNM - Daily change in the company's share price ATNM
Actinium Pharmaceuticals' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its radiopharmaceuticals for the treatment of blood cancer.
Daily change in the price of a set of shares in a market segment - Cancer blood
Actinium Pharmaceuticals, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with the dynamics of ATNM, which focuses on radiopharmaceuticals, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Actinium Pharmaceuticals is a biotech company developing radiopharmaceuticals for the treatment of blood cancer. Its shares move in sync with news about clinical trials, and their high volatility is part of the overall market movement where science meets finance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ATNM
For Actinium Pharmaceuticals, the year-to-date performance is a story about the development of targeted radiotherapy. Its 12-month market capitalization depends entirely on clinical trial data for its flagship drug, which is used to prepare patients for bone marrow transplants. Success could make it a new standard in this complex procedure.
Annual dynamics of market capitalization of the market segment - Cancer blood
Actinium Pharmaceuticals, Inc. is a biotech company pioneering the development of targeted radiotherapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the significant risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Actinium is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its radiopharmaceutical trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ATNM
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. Its monthly performance is driven by progress in late-stage clinical trials. News of its FDA approval and trial results for its lead drug, Iomab-B, are the main drivers.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Actinium Pharmaceuticals is a leader in the development of alpha-particle-based targeted radiotherapy for the treatment of blood cancers. This technology delivers high-powered radiation directly to tumor cells. The chart below reflects the current state of the blood cancer treatment sector, where Actinium offers an innovative approach.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Actinium Pharmaceuticals is a biotech company developing radiotherapy for blood cancer. Its stock is a classic biotech play, with its value driven by progress in clinical trials. Its dynamics are completely disconnected from the market and represent a bet on the approval of its drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ATNM
Actinium, a biopharmaceutical company developing radiotherapy for blood cancer, has seen extremely volatile weekly performance. News about the progress of clinical trials, particularly those for bone marrow transplants, has sparked strong investor reactions.
Weekly dynamics of market capitalization of the market segment - Cancer blood
Actinium shares, like those of the entire nuclear medicine sector, are moving against a backdrop of scientific breakthroughs and investment. Demand for new cancer treatments is driving them all. The chart will show how the company fares in this innovative, yet risky, field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Actinium shares, like those of the entire nuclear medicine sector, are moving against a backdrop of scientific breakthroughs and investment. Demand for new cancer treatments is driving them all. The chart will show how the company fares in this innovative, yet risky, field.
Market capitalization of the company, segment and market as a whole
ATNM - Market capitalization of the company ATNM
Actinium's market capitalization chart represents the financial valuation of a biotech company leading the field of targeted radiotherapy for blood cancer. It reflects investor expectations for its platform and lead drug, Iomab-B. Its dynamics tell the story of how the market evaluates the potential of this complex technology in late-stage clinical trials.
ATNM - Share of the company's market capitalization ATNM within the market segment - Cancer blood
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing actinium-225-based radioconjugates for targeted cancer radiation therapy. Its market share reflects its leadership in this promising area of nuclear medicine. The chart below is an indicator of market confidence in its technology.
Market capitalization of the market segment - Cancer blood
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. The chart below shows the total market capitalization of this entire sector. It reflects the search for "smart bombs" that deliver radiation to tumors. Actinium is one of the leaders in this promising field.
Market capitalization of all companies included in a broad market index - GURU.Markets
Radioimmunotherapy, shown in the graph, is a new approach to cancer treatment. Actinium Pharmaceuticals develops drugs that deliver radioactive isotopes to cancer cells, particularly in leukemia. Its capitalization represents a risky bet on this powerful but complex technology.
Book value capitalization of the company, segment and market as a whole
ATNM - Book value capitalization of the company ATNM
Actinium's book value is capital for radioconjugate therapy. Currently in the R&D stage, the company uses its financial assets to develop drugs that deliver the powerful radioisotope actinium-225 directly to cancer cells, particularly in the treatment of leukemia.
ATNM - Share of the company's book capitalization ATNM within the market segment - Cancer blood
Actinium Pharmaceuticals develops radioconjugates for cancer treatment. Its share of the sector's assets consists of its specialized laboratories and manufacturing facilities. This complex physical infrastructure is necessary for working with radioactive isotopes and antibodies.
Market segment balance sheet capitalization - Cancer blood
Actinium Pharmaceuticals is a radiopharmaceutical company, making it moderately capital-intensive. It doesn't require large factories, but it does require specialized laboratories and production facilities to handle radioactive isotopes. Compared to the biotech sector, its model requires unique physical assets.
Book value of all companies included in the broad market index - GURU.Markets
Actinium's assets are more than just antibodies; they're also the technology for "arming" them with powerful alpha-emitting isotopes for the targeted destruction of cancer cells. The company's balance sheet reflects the value of this radioconjugate platform. The chart shows the capital invested in developing this "magic bullet" for treating leukemia.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ATNM
Actinium Pharmaceuticals develops radioconjugates for targeted therapy of blood cancers. Its market value is derived from the valuation of its proprietary platform and leading candidates. Investors are buying a stake in a potential new standard of leukemia treatment.
Market to book capitalization ratio in a market segment - Cancer blood
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. This is a cutting-edge field in oncology. This chart shows the high premium the market pays for the potential of its technology to precisely deliver radiation to cancer cells, rather than for its tangible assets.
Market to book capitalization ratio for the market as a whole
Actinium Pharmaceuticals develops radiopharmaceuticals for cancer treatment. The company's market capitalization is based on the potential of this cutting-edge technology. The chart shows the significant premium investors are paying for research in one of the most promising areas of oncology, compared to the market average.
Debts of the company, segment and market as a whole
ATNM - Company debts ATNM
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. This cutting-edge technology requires significant investment in clinical trials and a complex production chain. Debt financing is an important part of securing capital to bring these drugs to market.
Market segment debts - Cancer blood
Actinium Pharmaceuticals is an oncology company specializing in radioimmunotherapy. Developing such complex drugs requires enormous investment. This chart shows how the company funds its expensive clinical trials, which are critical to bringing its cutting-edge blood cancer treatment technology to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ATNM
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. This chart shows the company's reliance on debt. This is a cutting-edge but very expensive area of oncology. The high debt means the company is placing a huge bet on the success of its technology, and any failure in trials would have dire financial consequences.
Market segment debt to market segment book capitalization - Cancer blood
Actinium Pharmaceuticals is developing radioconjugates for targeted radiation therapy for blood cancers, delivering radiation directly to tumor cells. This chart compares the debt raised for this cutting-edge research to the overall market capitalization of the entire sector. It illustrates the financial implications of creating "magic bullets" against leukemia.
Debt to book value of all companies in the market
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. This is a cutting-edge but capital-intensive field. The chart shows how the company finances its expensive clinical trials. Comparing its debt load with the biotech sector allows one to assess the financial risks and dependence on external capital on the path to commercialization.
P/E of the company, segment and market as a whole
P/E - ATNM
This chart for Actinium Pharmaceuticals, which is developing radioimmunotherapy for blood cancer, is a valuation of its high-tech platform. The stock price relative to future earnings reflects investors' faith in the effectiveness of its "magic bullet" therapy. The price action is a direct response to clinical trial data.
P/E of the market segment - Cancer blood
This chart reflects the average valuation for the speculative biotech sector—a benchmark for Actinium. For investors, it serves as a benchmark, indicating the overall level of optimism in the radiopharmaceuticals field. Against this backdrop, one can gauge expectations for the company's platform and its developments for treating blood cancer.
P/E of the market as a whole
Actinium Pharmaceuticals develops radioconjugates—drugs that deliver radioactive isotopes directly to cancer cells. This is a powerful treatment, particularly for blood cancers. This chart shows the market's risk appetite. It provides insight into how investors view the potential of this cutting-edge technology and how clinical trial results impact the company's valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ATNM
Actinium Pharmaceuticals is developing actinium-225-based radioconjugates for targeted cancer radiation therapy. This chart reflects analyst expectations for this cutting-edge field of oncology. It demonstrates market confidence that the company's technology will deliver powerful and precise tumor cell destruction with fewer side effects.
%20P%2FE%20ATNM&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ATNM&v=1772564539728 "Chart of the company's future (projected) P/E ATNM")
Future (projected) P/E of the market segment - Cancer blood
Actinium Pharmaceuticals develops radioconjugates for targeted cancer radiation therapy. This chart shows how its profitability expectations compare to the oncology sector. It reflects investor confidence in its technology, which delivers powerful radioactive isotopes directly to cancer cells, and in its lead drug, Iomab-B.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772564539835 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
Actinium Pharmaceuticals is developing radioconjugates for targeted cancer therapy. This chart shows the overall risk appetite. ATNM's success depends on clinical trial results. A positive market environment helps with funding but cannot replace scientific data, which is the primary driver of value.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772564539878 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ATNM
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing radioimmunotherapy for targeted radiation delivery to cancer cells. This chart shows the company's financial trajectory, based on cutting-edge nuclear medicine. The results reflect investments in clinical trials for the treatment of blood cancers.
Profit of companies in the market segment - Cancer blood
Actinium Pharmaceuticals is a biopharmaceutical company developing actinium-225-based radioconjugates for targeted cancer therapy, primarily leukemia. This is a cutting-edge field in nuclear medicine. This graph shows the total revenue in the oncology sector, reflecting the high interest in innovative methods that can destroy cancer cells with high precision.
Overall market profit
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. The company operates in cutting-edge medical fields, and its success depends on science. The need for treatment is independent of economic conditions. However, for funding capital-intensive clinical trials, positive investor sentiment, which often correlates with market growth, is essential.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ATNM
Actinium Pharmaceuticals is developing targeted radiotherapy that delivers powerful radioisotopes directly to cancer cells, primarily for the treatment of leukemia. This graph reflects analysts' expectations for the clinical and commercial success of this precision cancer treatment.
%20profit%20of%20the%20company%20ATNM&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ATNM&v=1772564540037 "Graph of future (projected) profit of the company ATNM")
Future (predicted) profit of companies in the market segment - Cancer blood
Actinium Pharmaceuticals is a biopharmaceutical company pioneering the development of targeted radiotherapy for cancer treatment. This chart shows forecasts for the innovative oncology sector. Actinium's future profitability depends on the success of its technology, which delivers high-powered radiation directly to cancer cells while minimizing harm to healthy tissue.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772564540049 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
Actinium Pharmaceuticals is developing radioconjugates for targeted cancer therapy. This cutting-edge field requires significant investment. This graph, which displays profit expectations, is an indicator of the overall investment climate, which determines how easily companies like Actinium will be able to raise capital for their research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772564540120 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ATNM
Actinium Pharmaceuticals is developing radioconjugate therapy for targeted cancer treatment. This chart shows that the company's valuation is based on the potential of its platform. It reflects investors' hopes that its drugs will become an important part of bone marrow transplant preparation regimens.
P/S market segment - Cancer blood
Actinium Pharmaceuticals is a biopharmaceutical company developing targeted radiotherapy based on actinium-225. Its technology delivers high-powered alpha radiation directly to cancer cells. This chart shows the average biotech valuation, which helps us understand how highly investors value the potential of this cutting-edge cancer treatment platform.
P/S of the market as a whole
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy, primarily for patients undergoing bone marrow transplantation. This is a niche but important area of oncology. This graph of average market revenue estimates clearly demonstrates that the company's valuation is based not on current sales, but on the potential of its drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ATNM
Actinium Pharmaceuticals develops radioimmunotherapy drugs for targeted cancer treatment, primarily leukemia. This chart reflects investor confidence in the future of this approach. The valuation is based on the potential revenue from its drugs, which deliver radiation directly to cancer cells, if approved.
%20P%2FS%20ATNM&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ATNM&v=1772564540193 "The graph of the company's future (projected) P/S ATNM")
Future (projected) P/S of the market segment - Cancer blood
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy, primarily for patients undergoing bone marrow transplantation. This chart compares the company's future revenue expectations with its industry sector. It reflects investor confidence in the potential of its unique technology in this niche medical field.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772564540240 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
Actinium Pharmaceuticals is a biopharmaceutical company developing radioconjugates for targeted cancer radiation therapy. This chart reflects confidence in future growth, and Actinium is at the forefront of oncology. The success of its platform could lead to the development of highly effective and precise treatments for blood cancers.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772564540270 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ATNM
Actinium Pharmaceuticals is a late-stage biopharmaceutical company specializing in radiation therapy for cancer. Because its lead candidate is preparing to submit for approval, the revenue shown in this chart comes from licensing agreements and grants, not sales.
Sales of companies in the market segment - Cancer blood
Actinium Pharmaceuticals is a leader in the development of radioconjugates for targeted radiation therapy for blood cancers. Their approach enables radiation delivery directly to cancer cells. This graph reflects progress in oncology, where innovative methods like Actinium's are opening up new avenues for the treatment of leukemia and lymphoma.
Overall market sales
Actinium Pharmaceuticals, Inc. develops radioconjugates for targeted cancer therapy. Its operations require significant investment. The growth in total revenue, reflected in this chart, creates a favorable investment climate. This facilitates raising the capital needed to conduct expensive clinical trials and bring products to market.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ATNM
Actinium Pharmaceuticals develops radioconjugates—drugs that deliver powerful alpha radiation directly to cancer cells, primarily for the treatment of leukemia. This graph reflects analysts' expectations for the success of clinical trials of this cutting-edge targeted radiation therapy.
%20sales%20of%20the%20company%20ATNM&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ATNM&v=1772564540479 "Schedule of future (projected) sales of the company ATNM")
Future (projected) sales of companies in the market segment - Cancer blood
Actinium Pharmaceuticals is a biopharmaceutical company developing radioconjugates for targeted cancer therapy. Its technology delivers high-power alpha radiation directly to cancer cells. This chart shows forecasts for the oncohematology sector, reflecting the potential of this innovative approach in the treatment of blood cancers.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772564540489 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
Actinium Pharmaceuticals, a developer of radiopharmaceuticals for cancer treatment, sees this chart as an indicator of investment activity in biotech. The strong economics reflected here facilitate the influx of capital needed to conduct clinical trials and bring a new class of targeted therapy to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772564540491 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ATNM
Actinium Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of radioconjugates for targeted cancer therapy. This chart reflects its current activities, which include significant investments in clinical research. It shows how capital is being used to advance this powerful treatment technology.
Market segment marginality - Cancer blood
Actinium Pharmaceuticals is developing targeted radiotherapy for the treatment of blood cancers. This approach requires complex production and logistics of radioactive isotopes. Efficiency is key to success. The chart demonstrates the competitiveness of their operating model, which combines pharmaceuticals and nuclear medicine.
Market marginality as a whole
Actinium Pharmaceuticals develops radioconjugates for targeted therapy for cancer patients. This graph shows average profitability, and Actinium operates at the forefront of nuclear medicine. Their financial success depends on the results of clinical trials of their drugs, which deliver radiation directly to cancer cells.
Employees in the company, segment and market as a whole
Number of employees in the company ATNM
Actinium Pharmaceuticals is a leader in targeted radiation therapy for cancer treatment. Its team, shown in this chart, includes experts in nuclear medicine and oncology. The growth is driven by the advancement of its lead drug, Iomab-B, through late-stage clinical trials.
Share of the company's employees ATNM within the market segment - Cancer blood
Actinium Pharmaceuticals is a leader in the development of targeted radiotherapy for the treatment of blood cancers. This approach requires unique expertise at the intersection of nuclear medicine and oncology. The chart shows the percentage of all specialists in this specialized field that Actinium attracts. This is a measure of its scientific leadership and the potential of its platform.
Number of employees in the market segment - Cancer blood
Actinium Pharmaceuticals is a biopharmaceutical company developing radioconjugates for targeted cancer therapy. Its core asset is its team of radiochemists and oncologists. This chart shows its research activity. The growth in staffing is an indicator of progress in late-stage clinical trials of its flagship programs.
Number of employees in the market as a whole
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. This cutting-edge field of medicine is driven by venture capital and scientific breakthroughs. This chart shows the big picture, but for Actinium, FDA approval of the drug will be a game-changer and require a dramatic expansion of its staff.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ATNM (ATNM)
Actinium Pharmaceuticals is a biotech company specializing in radiopharmaceuticals. Its market capitalization is based on the potential of its unique technology. This chart demonstrates that the market values the intellectual property created by a small team of scientists.
%20of%20the%20company%20ATNM%20(ATNM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ATNM-ATNM&v=1772564540616 "Chart of market capitalization per employee (in thousands of dollars) of the company ATNM (ATNM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
Actinium Pharmaceuticals develops radioconjugates for targeted cancer therapy. The company's value is based on the potential of its Iomab-B technology and other developments. This metric reflects how highly investors value this approach to cancer treatment, based on the team of scientists and clinicians working to bring it to market.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772564540629 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
Actinium Pharmaceuticals develops radioconjugates for targeted radiation therapy of cancer. This is a cutting-edge field of nuclear medicine. The graph shows a high employee rating, as the company is working on creating "magic bullets" that deliver radiation precisely to cancer cells, minimizing damage to healthy tissue.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772564540635 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ATNM (ATNM)
Actinium Pharmaceuticals is a biopharmaceutical company developing radiopharmaceuticals (targeted radiation) for the treatment of blood cancers, particularly before bone marrow transplants. This is an R&D business. This chart shows the burn rate of research capital per scientist.
%20Chart%20ATNM%20(ATNM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ATNM-ATNM&v=1772564540651 "Company Profit Per Employee (in thousands of dollars) Chart ATNM (ATNM)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
Actinium Pharmaceuticals (ATNM) is a biopharmaceutical company specializing in the development of radioconjugates (radiation-delivering antibodies) for the targeted treatment of blood cancers. This R&D effort is complex. This chart shows how efficiently the team of scientists and radiochemists utilizes capital to advance their candidates through expensive clinical trials.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772564540658 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
Actinium Pharmaceuticals is a biotech company developing radioimmunotherapy for cancer treatment. This is a highly complex field at the intersection of nuclear medicine and oncology. This chart shows that the company is deep in R&D. The negative profit per employee reflects the company's massive investment in its exceptional scientific staff and clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772564540706 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ATNM (ATNM)
Actinium Pharmaceuticals is developing radioconjugates for targeted cancer therapy. During clinical development, this graph is an indicator of future potential. Any revenue per employee will likely come from partnerships rather than commercial sales, but it will signal progress in this complex field.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ATNM-ATNM&v=1772564540750 "Sales chart per company employee ATNM (ATNM)")
Sales per employee in the market segment - Cancer blood
Actinium Pharmaceuticals is a leader in the development of targeted radiotherapy (alpha emitters) to prepare patients for bone marrow transplants. This chart shows the average revenue per employee in the sector. It serves as a benchmark in this complex field of oncology, demonstrating the level of productivity required to bring these sophisticated treatments to market.
Sales per employee for the market as a whole
Actinium Pharmaceuticals (ATNM) is a biotech company developing targeted radiotherapy. They "arm" antibodies with radioisotopes to precisely destroy cancer cells (for example, in preparation for a bone marrow transplant). This is R&D. This graph shows the current (zero) commercial return.
Short shares by company, segment and market as a whole
Shares shorted by company ATNM (ATNM)
Actinium Pharmaceuticals is developing targeted radiotherapy (ARC) for the treatment of blood cancers, using alpha emitters to deliver radiation to cells. This is a complex technology. The chart shows the number of investors betting that the company will encounter production issues or that its therapy will be too toxic for patients.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ATNM-ATNM&v=1772564540853 "Short Shares Chart for the Company ATNM (ATNM)")
Shares shorted by market segment - Cancer blood
Actinium Pharmaceuticals is a pioneer in radiopharmaceuticals, "arming" antibodies with alpha emitters to precisely destroy blood cancers. This chart reflects skepticism about this entire niche. Its growth suggests investors are concerned about logistics or safety issues with radiopharmaceuticals, which poses a barrier to the entire industry.
Shares shorted by the overall market
Actinium Pharmaceuticals specializes in targeted radiotherapy, particularly for bone marrow transplant preparation. It's a niche but important biotech. This chart measures overall fear. When the market is pessimistic, investors sell off biotechs without profits. ATNM shares, dependent on trial news, become extremely volatile during periods of risk aversion.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ATNM (ATNM)
Actinium Pharmaceuticals is developing targeted radiation therapy for the treatment of blood cancers. This is a promising but risky area. This indicator tracks the stock's momentum, which is entirely dependent on trial news. It indicates extreme optimism (above 70) or deep pessimism (below 30) among investors awaiting FDA decisions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ATNM-ATNM&v=1772564540979 "RSI 14 indicator chart for the company's stock ATNM (ATNM)")
RSI 14 Market Segment - Cancer blood
Actinium (ATNM) is "alpha" radiation against cancer. They are *leaders* in *targeted alpha therapy* (TAT) using *actinium-225* to treat *blood cancer*. The "Cancer Blood" sector (biotech/radiopharmaceuticals) is living on hype. RSI\_14\_Seg shows the "temperature" of the *entire* industry. It helps us understand: is ATNM's growth a niche product or a general hype?
RSI 14 for the overall market
Actinium Pharmaceuticals (ATNM) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ATNM (ATNM)
Actinium Pharmaceuticals is a biotech company developing "radioconjugates"—drugs that deliver radiation (actinium-225) precisely to cancer cells in the blood. This chart shows the analysts' average 12-month forecast. It represents their collective bet on the success of this complex R&D platform in treating leukemia.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ATNM-ATNM&v=1772564541068 "A chart showing analyst consensus forecasts for the expected stock price. ATNM (ATNM)")
The difference between the consensus estimate and the actual stock price ATNM (ATNM)
Actinium Pharma is a leader in targeted alpha therapy. The company "arms" antibodies with powerful radioactive isotopes to destroy cancer cells (primarily leukemia). This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe in this cutting-edge oncology technology (Iomab-B).
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ATNM-ATNM&v=1772564541074 "A chart showing the difference between the consensus forecast and the actual stock price. ATNM (ATNM)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
Actinium is a pioneer in targeted radiotherapy. The company attaches alpha emitters to antibodies to precisely deliver radiation to cancer cells (especially in leukemia). This chart shows analysts' overall expectations for the blood cancer sector. It reflects whether experts believe radiopharma will become a new pillar of oncology.
Analysts' consensus forecast for the overall market share price
Actinium Pharmaceuticals is a biotech company specializing in "radioimmunotherapy." They attach radioactive isotopes to antibodies to target cancer cells (primarily leukemia). This chart shows the overall risk appetite. For Actinium, working in a cutting-edge but complex field, overall market optimism is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ATNM
Actinium is a pioneer in targeted radiotherapy. Their platform attaches a powerful radioactive isotope (Actinium-225) to antibodies, creating a magic bullet designed to seek out and destroy cancer cells, particularly blood cancers. This chart is a pure R&D barometer. It reflects market expectations for this radiotherapy, their progress in clinical trials, and their manufacturing challenges.
AKIMA Market Segment Index - Cancer blood
Actinium Pharmaceuticals (ATNM) is a leader in targeted radiotherapy (Alpha-Particle Therapy). They arm antibodies with alpha emitters to precisely destroy cancer cells, primarily in the treatment of leukemia. The chart shows the segment's average index, helping investors assess how this advanced but complex technology compares to the average in the blood cancer sector.
The AKIM Index for the overall market
Actinium Pharmaceuticals is a biotech company developing targeted radiotherapy (ARC) for the treatment of leukemia and bone marrow transplant preparation. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this late-stage radiopharma story compares to overall economic trends.
